Eli Lilly and Co. is seeking to raise approximately $8 billion through an investment-grade bond sale.
The drugmaker intends to use the capital for recent and future acquisitions.
The offering reportedly includes as many as eight separate parts.
Maturities for the debt range from two to 40 years.
Lilly recently executed multi-billion dollar deals for Centessa Pharmaceuticals and Kelonia Therapeutics.
The bond sale follows the company reporting strong first-quarter results.
Management recently increased the financial forecast for 2026.
High demand for weight-loss medications remains the primary driver of the company's growth.